1939 - Who to Boost When: An Analysis of Dosing Interval and Age on COVID-19 Outcomes in the COVE Trial During the Delta and Omicron Waves

Presenting Author(s)

• 

  Dean Follmann, PhD (he/him/his)

  Assistant Director for Biostatistics
  National Institute of Allergy and Infectious Disease
  Bethesda, MD, United States

  Slides

Co-Author(s)

• XW

  Xiaowei Wang, PhD

  Moderna, Inc.
  Cambridge, Massachusetts, United States
• PG

  Peter Gilbert, PhD

  Professor
  Fred Hutchinson Cancer Center
  Seattle, Washington, United States
• 

  Lindsey R. Baden, MD

  Attending Physician
  Brigham and Women's Hospital
  Boston, MA, United States
• 

  Hana M. El Sahly, MD

  Professor
  Baylor College of Medicine
  Houston, TX, United States
• 

  Brandon Essink, M.D.

  Principal Investigator
  Meridian Clinical Research
  Omaha, Nebraska, United States
• MM

  Mary Marovich, M.D.

  Director, Vaccine Research Program
  National Institute of Allergy and Infectious Diseases, National Institutes of Health
  Bethesda, Maryland, United States
• HJ

  Holly Janes, PhD

  Professor
  Fred Hutchinson Cancer Research Center
  Seattle, WA, United States
• WD

  Weiping Deng, PhD

  Moderna, Inc.
  Cambridge, Massachusetts, United States
• FP

  Frances Priddy, MD, MPH

  Moderna, Inc.
  Cambridge, Massachusetts, United States
• AD

  Avika Dixit, MBBS

  Moderna, Inc.
  Cambridge, Massachusetts, United States
• JT

  Joanne Tomassini, Ph.D.

  Moderna, Inc.
  Cambridge, Massachusetts, United States
• RD

  Rituparna Das, M.D.

  Moderna, Inc.
  Cambridge, Massachusetts, United States
• JM

  Jacqueline Miller, MD

  Moderna, Inc.
  Cambridge, Massachusetts, United States
• HZ

  Honghong Zhou, Ph.D.

  Moderna, Inc.
  Cambridge, Massachusetts, United States